Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets, further reinforcing its leading global position in antibiotics.
Brand Name : Zinnat
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 11, 2021
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Sandoz B2B
Deal Size : $500.0 million
Deal Type : Divestment
GSK to Sell Cephalosporin Antibiotics Business to Sandoz
Details : Cephalosporin manufacturing will transfer from GSK sites to Sandoz following a four-year manufacturing and supply agreement (MSA) and subsequent transfer of manufacturing operations.
Brand Name : Zinnat
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 11, 2021
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Sandoz B2B
Deal Size : $500.0 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?
Reset All
